Similarly, for zccs250 (patient with anaplastic large cell lymphoma) with an NPM–ALK fusion and clinical CR to the ALK inhibitor, ceritinib, therapeutic response was recapitulated in the mouse PDX and a significant response was observed in the zebrafish PDX model (Fig 2B; Supplementary Fig. S3B). This evidence concerns the gene ALK and anaplastic large cell lymphoma.